Steven Lichtman
Stock Analyst at Oppenheimer
(3.13)
# 1,227
Out of 4,970 analysts
68
Total ratings
45.83%
Success rate
13.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $80.55 | +26.63% | 9 | Jul 31, 2025 | |
| BSX Boston Scientific | Maintains: Perform | $110 → $118 | $107.27 | +10.01% | 3 | Jul 24, 2025 | |
| PODD Insulet | Maintains: Outperform | $312 → $324 | $346.49 | -6.49% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $104.67 | +28.98% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.29 | +126.84% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $78.78 | +39.64% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $92.79 | +1.30% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $8.45 | +669.23% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $12.27 | +372.70% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $15.87 | -30.69% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $10.62 | +12.99% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $91.30 | -4.71% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.70 | +398.43% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $394.04 | -26.91% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $91.24 | +15.08% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $27.76 | +440.35% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $67.38 | +26.15% | 3 | Sep 4, 2020 |
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $80.55
Upside: +26.63%
Boston Scientific
Jul 24, 2025
Maintains: Perform
Price Target: $110 → $118
Current: $107.27
Upside: +10.01%
Insulet
May 9, 2025
Maintains: Outperform
Price Target: $312 → $324
Current: $346.49
Upside: -6.49%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $104.67
Upside: +28.98%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.29
Upside: +126.84%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $78.78
Upside: +39.64%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $92.79
Upside: +1.30%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $8.45
Upside: +669.23%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $12.27
Upside: +372.70%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $15.87
Upside: -30.69%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $10.62
Upside: +12.99%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $91.30
Upside: -4.71%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.70
Upside: +398.43%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $394.04
Upside: -26.91%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $91.24
Upside: +15.08%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $27.76
Upside: +440.35%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $67.38
Upside: +26.15%